Related Experiment Video
Updated: Jun 16, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Hydroxyurea for children with sickle cell disease
Matthew M Heeney1, Russell E Ware
1Department of Pediatrics, Harvard Medical School, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. matthew.heeney@childrens.harvard.edu
Insights
Hydroxyurea therapy shows promise for children with sickle cell disease (SCD). While effective and safe for managing sickling and organ damage, more data are needed on long-term risks and organ protection.
Area of Science:
- Pediatric Hematology
- Pharmacology
- Genetic Blood Disorders
Background:
- Sickle cell disease (SCD) is a serious inherited blood disorder.
- Current treatments aim to manage symptoms and prevent complications.
- Hydroxyurea is a key therapeutic agent for SCD.
Purpose of the Study:
- To evaluate the efficacy and safety of hydroxyurea in pediatric SCD.
- To understand hydroxyurea's mechanisms in addressing SCD pathophysiology.
- To identify gaps in knowledge regarding long-term outcomes and organ protection.
Main Methods:
- Review of existing data on hydroxyurea therapy in children with SCD.
- Analysis of hydroxyurea's known mechanisms of action.
- Identification of areas requiring further clinical investigation.
Main Results:
- Hydroxyurea effectively addresses sickling, vaso-occlusion, hemolysis, and organ damage.
- The therapy is generally well-tolerated with a wide therapeutic window.
- Limited data exist on preventing organ dysfunction and long-term risks.
Conclusions:
- Hydroxyurea is an effective, yet underutilized, treatment for pediatric SCD.
- Further research is crucial to define long-term benefits and risks.
- Clinical trials are ongoing to provide more comprehensive data.
Abstract:
Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage. There are limited data regarding hydroxyurea's ability to prevent or diminish organ dysfunction, and the long-term risks of hydroxyurea therapy remain incompletely defined. Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Dosing: Infants and Children
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
